News

Doctors warned to be wary of new drugs

BMJ 2002; 324 doi: 10.1136/bmj.324.7346.1113 (Published 11 May 2002)
Cite this as: BMJ 2002;324:1113.1

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Deborah Josefson
  1. Nebraska

    Doctors should be wary of starting their patients on newly approved drugs, because of the high rate of adverse side effects that go undetected until late in the post-marketing surveillance period, a new study says (JAMA 2002;287:2215-20).

    More than 10% of new drugs approved by the Food and Drug Administration (FDA) have serious side effects that are not discovered on initial testing and marketing, says the study, led by Dr Karen Lasser and Dr Paul Allen of the Department of Medicine at Cambridge Hospital in Cambridge, Massachusetts.

    The investigators analysed 548 drugs approved by the FDA from 1975 to 1999. The list …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular